DK3352735T3 - Olanzapinformuleringer med langvarig frigivelse - Google Patents

Olanzapinformuleringer med langvarig frigivelse Download PDF

Info

Publication number
DK3352735T3
DK3352735T3 DK16775424.1T DK16775424T DK3352735T3 DK 3352735 T3 DK3352735 T3 DK 3352735T3 DK 16775424 T DK16775424 T DK 16775424T DK 3352735 T3 DK3352735 T3 DK 3352735T3
Authority
DK
Denmark
Prior art keywords
olanzap
disclosures
extended
release
release disclosures
Prior art date
Application number
DK16775424.1T
Other languages
English (en)
Inventor
Mark Alan Smith
Carine Claassen-Punt
Original Assignee
Teva Pharmaceuticals Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals Int Gmbh filed Critical Teva Pharmaceuticals Int Gmbh
Application granted granted Critical
Publication of DK3352735T3 publication Critical patent/DK3352735T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Biological Depolymerization Polymers (AREA)
DK16775424.1T 2015-09-21 2016-09-21 Olanzapinformuleringer med langvarig frigivelse DK3352735T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562221290P 2015-09-21 2015-09-21
PCT/US2016/052757 WO2017053346A1 (en) 2015-09-21 2016-09-21 Sustained release olanzapine formulations

Publications (1)

Publication Number Publication Date
DK3352735T3 true DK3352735T3 (da) 2023-10-30

Family

ID=57047342

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16775424.1T DK3352735T3 (da) 2015-09-21 2016-09-21 Olanzapinformuleringer med langvarig frigivelse

Country Status (21)

Country Link
US (4) US20170079985A1 (da)
EP (2) EP4331570A1 (da)
JP (2) JP2018527397A (da)
KR (1) KR20180054627A (da)
CN (2) CN108289834A (da)
AR (1) AR106085A1 (da)
AU (2) AU2016328958B2 (da)
CA (1) CA2998504C (da)
CL (1) CL2018000727A1 (da)
DK (1) DK3352735T3 (da)
EA (1) EA201890788A1 (da)
ES (1) ES2960753T3 (da)
FI (1) FI3352735T3 (da)
HU (1) HUE063850T2 (da)
IL (3) IL295161A (da)
MX (2) MX2018003380A (da)
NZ (1) NZ740665A (da)
PL (1) PL3352735T3 (da)
PT (1) PT3352735T (da)
TW (1) TWI798161B (da)
WO (1) WO2017053346A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3600258A1 (en) 2017-03-20 2020-02-05 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulaitons
EP3735223A4 (en) * 2018-01-05 2021-10-13 Impel Neuropharma Inc. INTRANASAL ADMINISTRATION OF OLANZAPINE BY A PRECISION OLFACTORY DEVICE
IL294089B1 (en) * 2019-12-20 2026-07-01 Alar Pharmaceuticals Inc Injectable, long-acting formulations of ketamine pamoate salts
CN112587505A (zh) * 2020-10-16 2021-04-02 长春斯菲尔生物科技有限公司 一种奥氮平双羟萘酸盐缓释微粒制剂及其制备方法
WO2025188992A1 (en) * 2024-03-06 2025-09-12 Neurelis, Inc. Oral film for rapid active delivery

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
AU752552C (en) * 1997-09-30 2003-09-11 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
ATE410186T1 (de) 2003-06-26 2008-10-15 Control Delivery Sys Inc In-situ gelierendes arzneimittelabgabesystem
KR101242486B1 (ko) 2004-01-12 2013-03-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 장기 전달을 위한 제형 및 그의 이용 방법
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile
NL1026261C2 (nl) 2004-05-25 2005-11-28 Nanomi B V Sproei inrichting met een nozzleplaat voorzien van structuren ter bevordering van self-breakup, een nozzleplaat, alsmede werkwijzen ter vervaardiging en toepassing van een dergelijke nozzleplaat.
PL1768650T3 (pl) 2004-06-04 2009-01-30 Camurus Ab Ciekłe formulacje depot
EP2623095A1 (en) * 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
CA2605153A1 (en) * 2005-04-13 2006-10-19 Jaymin Chandrakant Shah Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
CA2603189A1 (en) * 2005-04-13 2006-10-19 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
CN106075449A (zh) * 2005-07-14 2016-11-09 尼奥塞蒂克斯公司 用于局部脂肪组织治疗的持续释放的增强性脂肪分解性制剂
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
WO2007139744A2 (en) 2006-05-23 2007-12-06 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst
EP2054073B1 (en) 2006-07-11 2014-11-26 Foresee Pharmaceuticals, Inc. Pharmaceutical compositions for sustained release delivery of peptides
FI20070174A0 (fi) 2007-02-28 2007-02-28 Delsitech Oy Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt
KR100805208B1 (ko) 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
WO2008130158A1 (en) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
ES2324009B1 (es) 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
JP5222550B2 (ja) * 2007-12-27 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US20090263443A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedics, Inc. Methods for treating post-operative effects such as spasticity and shivering with clondine
US8877225B2 (en) 2008-06-03 2014-11-04 Tolmar Therapeutics, Inc. Controlled release copolymer formulation with improved release kinetics
KR101626632B1 (ko) 2008-08-12 2016-06-01 노파르티스 아게 제약 조성물
WO2010040188A1 (en) 2008-10-10 2010-04-15 The Bionic Ear Institute Biodegradable polymer - bioactive moiety conjugates
EA201100765A1 (ru) 2008-12-15 2012-04-30 Бинд Биосаиэнсис Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств
CA2792484C (en) 2009-03-12 2017-10-31 Delpor, Inc. Implantable device for long-term delivery of drugs
US8758780B2 (en) 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
WO2011080733A1 (en) 2010-01-04 2011-07-07 Mapi Pharma Limited Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
EP2343046A1 (en) 2010-01-08 2011-07-13 Nirvana's Tree House B.V. Functionalised triblock copolymers and compositions containing such polymers
SI2394663T1 (sl) 2010-05-31 2022-02-28 Laboratorios Farmaceuticos Rovi, S.A. Sestave za injicirane biološko razgradljive vsadke in situ
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
FR2968994B1 (fr) 2010-12-17 2012-12-28 Flamel Tech Sa Procede de preparation de nanoparticules
MY165655A (en) 2010-12-29 2018-04-18 Medincell Biodegradable drug delivery compositions
LT2717914T (lt) 2011-06-10 2020-03-25 Ramscor, Inc. Sulėtinto atpalaidavimo kompozicijos, skirtos baltymų pateikimui į akį, ir jų paruošimo būdai
WO2013063125A1 (en) 2011-10-24 2013-05-02 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions and methods of treatment thereof
JP6282231B2 (ja) 2012-01-23 2018-02-21 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子
CN103417492A (zh) * 2012-05-25 2013-12-04 上海现代药物制剂工程研究中心有限公司 含有奥氮平的生物降解微球制剂及其制备方法
US20140323517A1 (en) 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system
PT3010962T (pt) 2013-06-20 2017-09-05 Pharmathen Sa Preparação de micropartículas polilactida-poliglicolida com um perfil de libertação sigmoide
CN103877005A (zh) * 2014-03-26 2014-06-25 陈德香 一种复方奥氮平皮下埋植缓释剂

Also Published As

Publication number Publication date
AR106085A1 (es) 2017-12-13
WO2017053346A1 (en) 2017-03-30
US20180264001A1 (en) 2018-09-20
IL275735A (en) 2020-08-31
IL295161A (en) 2022-09-01
CA2998504A1 (en) 2017-03-30
TWI798161B (zh) 2023-04-11
JP2018527397A (ja) 2018-09-20
TW201726144A (zh) 2017-08-01
US20170079985A1 (en) 2017-03-23
NZ740665A (en) 2023-04-28
US20240238307A1 (en) 2024-07-18
PL3352735T3 (pl) 2024-01-29
AU2022206695A1 (en) 2022-08-11
PT3352735T (pt) 2023-10-30
JP2021167331A (ja) 2021-10-21
MX2018003380A (es) 2018-08-16
CN108289834A (zh) 2018-07-17
IL258086A (en) 2018-05-31
EP3352735A1 (en) 2018-08-01
EA201890788A1 (ru) 2018-09-28
US20220323458A1 (en) 2022-10-13
AU2016328958B2 (en) 2022-04-21
CA2998504C (en) 2023-06-20
ES2960753T3 (es) 2024-03-06
CN116942677A (zh) 2023-10-27
EP4331570A1 (en) 2024-03-06
FI3352735T3 (fi) 2023-10-20
HUE063850T2 (hu) 2024-02-28
MX2022007315A (es) 2022-07-13
KR20180054627A (ko) 2018-05-24
EP3352735B1 (en) 2023-08-30
AU2016328958A1 (en) 2018-04-05
HK1255946A1 (en) 2019-09-06
CL2018000727A1 (es) 2018-09-28

Similar Documents

Publication Publication Date Title
FIC20230006I1 (fi) Vutrisiraani
EP3374114A4 (en) WORKBENCH
DK3283625T3 (da) Nukleasemedieret genomeditering
EP3286361A4 (en) Cancer neoepitopes
DK3331869T3 (da) Muscarinagonister
DK3331528T3 (da) Muskarinagonister
DK3277719T3 (da) Polypeptider
EP3316375A4 (en) Redox flow cell
DK3360890T3 (da) Genterapi
DK3305788T3 (da) Janus-kinase-hæmmer
PT3298027T (pt) Compostos depsipéptidos antelmínticos
DK3331529T3 (da) Muskarinagonister
EP3290364A4 (en) Conveyor belt wear monitoring system
DK3310450T3 (da) Olie-vand-separator
LT3386954T (lt) Dimeriniai kontrastiniai agentai
DK3394281T3 (da) Gærcelle
EP3297518B1 (en) VIDEO LARYNGOSCOPES
DK3270930T3 (da) Præeklampsi
EP3381654A4 (en) Liquid blow molding method
EP3393959A4 (en) GRAB
EP3363322A4 (en) Hair extender
DK3292136T3 (da) Penicillin-g-acylaser
DK3274482T3 (da) Stenborsknop
EP3390373C0 (en) DOTA SUMMARY
EP3548009A4 (en) POLYMANANOPARTICLE